| Methods |
R = randomisation tables, stratified for gender
C = sequentially numbered containers from pharmacy
Double blind
Exclusions during trials: none
Losses to follow‐up: none |
| Participants |
Sweden
441 participants
226 (51%) male
100% CT before entry
Ischaemic stroke less than 72 hours since stroke onset
SSSS 1 point or more |
| Interventions |
Rx: aspirin 325 mg orally once daily
Control: placebo
Duration: 5 days |
| Outcomes |
Death
2 points or more (may be in different items) worsening on SSSS at 5 days
Ability to walk unaided, increased need for ADL help at 3 months |
| Notes |
Ex: specified by protocol ‐ includes severe concomitant medical conditions or pre‐existing neurological illness, bleeding risk, blood pressure above 240/140 mmHg
FU: 3 months |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment (selection bias) |
Low risk |
A ‐ Adequate |
